Drug Profile

CLM 022

Alternative Names: CLM-022

Latest Information Update: 25 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Celloram
Developer Genfit
Class Anti-inflammatories; Hepatoprotectants; Small molecules; Triterpenes
Mechanism of Action Antioxidants; NLRP3 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Inflammatory bowel diseases; Liver disorders

Most Recent Events

22 Sep 2025 Genfit plans a first-in-human trial in liver disorders in the first half of 2027
07 May 2025 Pharmacodynamics data from a preclinical trial in Liver disorders presented at the European Association for the Study of the Liver Congress 2025 (EASL-2025)
24 Apr 2025 Genfit plans a formulation development and first toxicological studies in liver disorders in 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com